Literature DB >> 11553218

Surgical therapy for adenocarcinoma of the cardia: modalities of recurrence and extension of resection.

S Mattioli1, M P Di Simone, L Ferruzzi, F D'Ovidio, V Pilotti, R Carella, A D'Errico, W F Grigioni.   

Abstract

In order to define the optimal extent of resection for cancer of the cardia, we considered 116 patients operated upon with five different surgical techniques. The procedures were: transabdominal total gastrectomy associated with distal esophagectomy in 38 patients; transabdominal total gastrectomy and left thoracotomic esophageal resection at the inferior pulmonary vein level in 26 patients; transabdominal total gastrectomy and right thoracotomic esophageal resection at the azygos vein level in 27 patients; transabdominal total gastrectomy and transhiatal lower third esophagectomy in 18 patients; transhiatal total esophagectomy and upper third gastrectomy with cervical esophago-gastroplasty in seven patients. Grading, staging, neoplastic lymphangitis, satellite intramural metastases, infiltration of the resection margin, site of recurrence, and survival were analyzed. N+ was the single independent prognostic factor for survival. A poorly differentiated grading was related to T (P = 0.0009), N (P = 0.001), satellite growth (P = 0.05), and infiltration of the resection margin (P = 0.0001). Recurrence was local in 26% and distant in 74% of patients. The modalities of recurrence were not related to the aggressiveness parameters and the surgical technique. Infiltration of the esophageal resection margin was related to the type of operation (P = 0.005) and survival (P = 0.02), but it was not related to the site of recurrence. Transabdominal total gastrectomy and the right thoracotomic esophageal resection procedure achieved free margins and control of the lymph nodal metastatic spread. Transabdominal total gastrectomy and right thoracotomic esophageal resection at the azygos vein level provides a radical oncologic resection, particularly in poorly differentiated tumors. However, surgery alone cannot cure the majority of adenocarcinomas of the cardia.

Entities:  

Mesh:

Year:  2001        PMID: 11553218     DOI: 10.1046/j.1442-2050.2001.00165.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  6 in total

1.  Outcomes of Abdominal Total Gastrectomy for Type II and III Gastroesophageal Junction Tumors: Single Center's Experience in Korea.

Authors:  Kyoung Tai Kim; Oh Jeong; Mi Ran Jung; Seong Yeop Ryu; Young-Kyu Park
Journal:  J Gastric Cancer       Date:  2012-03-30       Impact factor: 3.720

Review 2.  Oncologic Quality Indicators in Thoracic Surgery.

Authors:  Jessica Hudson; Tara Semenkovich; Varun Puri
Journal:  Thorac Surg Clin       Date:  2017-08       Impact factor: 1.750

3.  Clinicopathologic comparison of Siewert type II and III adenocarcinomas of the gastroesophageal junction.

Authors:  Norihiro Yuasa; Hideo Miyake; Tatsuharu Yamada; Tomoki Ebata; Yuji Nimura; Tatsuo Hattori
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

4.  Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome.

Authors:  Andrew P Barbour; Nabil P Rizk; Mithat Gonen; Laura Tang; Manjit S Bains; Valerie W Rusch; Daniel G Coit; Murray F Brennan
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

5.  Safety and feasibility of preoperative exercise training during neoadjuvant treatment before surgery for adenocarcinoma of the gastro-oesophageal junction.

Authors:  J F Christensen; C Simonsen; A Banck-Petersen; S Thorsen-Streit; A Herrstedt; S S Djurhuus; C Egeland; C E Mortensen; S C Kofoed; T S Kristensen; R S Garbyal; B K Pedersen; L B Svendsen; P Højman; P de Heer
Journal:  BJS Open       Date:  2018-10-24

6.  The impact of operative approach on outcome of surgery for gastro-oesophageal tumours.

Authors:  Stuart A Suttie; Alan Gk Li; Martha Quinn; Kenneth Gm Park
Journal:  World J Surg Oncol       Date:  2007-08-20       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.